EU-ADR
Exploring and understanding adverse drug reactions by integrative mining of clinical records and biomedical knowledge
| Coordinatore | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: DR. MOLEWATERPLEIN 40/50 230 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 5˙871˙496 € |
| EC contributo | 4˙500˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2007-1 |
| Funding Scheme | CP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2012-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: DR. MOLEWATERPLEIN 40/50 230 contact info |
NL (ROTTERDAM) | coordinator | 0.00 |
| 2 |
AARHUS UNIVERSITETSHOSPITAL
Organization address
address: NORREBROGADE contact info |
DK (AARHUS) | participant | 0.00 |
| 3 |
AGENZIA REGIONALE DI SANITA
Organization address
address: VIA VITTORIO EMANUELE II 64 contact info |
IT (FIRENZE) | participant | 0.00 |
| 4 |
ASTRAZENECA AB
Organization address
address: Vastra Maelarhamnen contact info |
SE (SODERTAELJE) | participant | 0.00 |
| 5 |
FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM
Organization address
address: Doctor Aiguader contact info |
ES (BARCELONA) | participant | 0.00 |
| 6 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 0.00 |
| 7 |
PHARMO COOPERATIE UA
Organization address
address: VAN DEVENTERLAAN contact info |
NL (UTRECHT) | participant | 0.00 |
| 8 |
SOCIETA SERVIZI TELEMATICI SRL
Organization address
address: VIA MEDICI GIACOMO 9/A contact info |
IT (PADOVA) | participant | 0.00 |
| 9 |
THE UNIVERSITY OF NOTTINGHAM
Organization address
address: University Park contact info |
UK (NOTTINGHAM) | participant | 0.00 |
| 10 |
UNIVERSIDADE DE AVEIRO
Organization address
address: CAMPO UNIVERSITARIO DE SANTIAGO contact info |
PT (AVEIRO) | participant | 0.00 |
| 11 |
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
Organization address
address: PAZO DE SAN XEROME, PRAZA DO OBRADOIRO contact info |
ES (SANTIAGO DE COMPOSTELA) | participant | 0.00 |
| 12 |
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Organization address
address: PIAZZA DELL'ATENEO NUOVO contact info |
IT (MILANO) | participant | 0.00 |
| 13 |
UNIVERSITAT POMPEU FABRA
Organization address
address: PLACA DE LA MERCE 10-12 contact info |
ES (BARCELONA) | participant | 0.00 |
| 14 |
UNIVERSITE VICTOR SEGALEN BORDEAUX II
Organization address
address: RUE LEO SAIGNAT 146 contact info |
FR (BORDEAUX CEDEX) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Serious adverse effects resulting from the treatment with thalidomide prompted modern drug legislation more than 40 years ago. Post-marketing spontaneous reporting systems for suspected adverse drug reactions (ADRs) have been a cornerstone to detect safety signals in pharmacovigilance. It has become evident that adverse effects of drugs may be detected too late, when millions of persons have already been exposed.In this project, an alternative approach for the detection of ADR signals will be developed. Rather than relying on the physician's capability and willingness to recognize and report suspected ADRs, the system will systematically calculate the occurrence of disease (potentially ADRs) during specific drug use based on data available in electronic patient records. In this project, electronic health records (EHRs) of over 30 million patients from several European countries will be available. In an environment where rapid signal detection is feasible, rapid signal assessment is equally important. To rapidly assess signals, a number of resources will be used to substantiate the signals: causal reasoning based on information in the EHRs, semantic mining of the biomedical literature, and computational analysis of biological and chemical information (drugs, targets, anti-targets, SNPs, pathways, etc.).The overall objective of this project is the design, development and validation of a computerized system that exploits data from electronic healthcare records and biomedical databases for the early detection of adverse drug reactions. The EU-ADR system will generate signals using data and text mining, epidemiological and other computational techniques, and subsequently substantiate these signals in the light of current knowledge of biological mechanisms and in silico prediction capabilities. The system should be able to detect signals better and faster than spontaneous reporting systems and should allow for identification of subpopulations at higher risk for ADRs.